Other strategies have been exploited to promote mitochondrial FAO to treat metabolic diseases either via targeting CPT1 or ACC, for example, using PPAR agonists, metformin or certain natural drug treatment, or overexpressing a CPT1 mutant to boost the activities (Dai et al., 2018; Hong et al., 2014; Lee et al., 2018). This evidence concerns the gene CPT2 and metabolic disease.